Biologic agents in the treatment of inflammatory rheumatic diseases.
In 1997, knowledge about the treatment of autoimmune rheumatic diseases increased further. The most promising data to date came from studies using tumor necrosis factor-alpha blocking agents, such as monoclonal antibodies or soluble receptor constructs. Clinical trials with these compounds have now advanced to phase III; however, long-term safety data are not yet available. In addition, new developments with regard to T-helper cell-directed treatment principles, anti-inflammatory cytokines, and adhesion molecules are discussed.
Kalden
J R
JR
Medizinische Klinik III mit Poliklinik, Friedrich-Alexander Universität Erlangen-Nürnberg, Germany.
Manger
B
B
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015704:CD4 Antigens / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D012216:Rheumatic Diseases / Q000276:immunology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D016207:Cytokines; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1